Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen will gain antibody technologies designed to discover and develop new molecules with broad applications across therapeutic areas

Employee wellbeing in creative agencies: three tips to get you started

Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration

Fox&Cat

Managing unhelpful pressure in your creative agency: the human approach

Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?

Fox&Cat

- PMLiVE

AbbVie reveals new data for presbyopia eye drop treatment

Opthalmic solution is currently being reviewed by the US Food and Drug Administration

- PMLiVE

The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model

By Siobhan Reilly

Biogen Idec building

Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate

The phase 1b study demonstrated an encouraging safety and tolerability profile in patients with mild Alzheimer’s disease

- PMLiVE

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a bid to protect Remicade

dengue fever mosquito

BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine

The company aims to develop a vaccine candidate and also boost mRNA manufacturing capabilities on the African continent

- PMLiVE

Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels

South Korea-based study found AZ followed by Pfizer boosted antibody levels six-fold compared to two AZ doses

- PMLiVE

AZ’s PNH therapy Ultomiris wins EU backing to expand use for children

The positive recommendation is based on interim results from a phase 3 trial

- PMLiVE

CHMP rejects Kyowa Kirin’s Parkinson’s disease drug

Results of eight main studies of drug were 'inconsistent', according to the CHMP

- PMLiVE

Google’s DeepMind opens ‘breakthrough’ protein database to the world

AI company has mapped the structure of 98.5% of the proteins in the human body

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links